Final Analysis of Intergroup Randomized Phase III Study of Androgen Deprivation Therapy (ADT) ± Radiation Therapy (RT) in Locally Advanced Prostate Cancer (NCIC-CTG, SWOG, MRC-UK, INT: T94-0110; NCT00002633)

occurred in 10.6% and 11.5% of patients in the Ra-223 and placebo groups, respectively; grade 3/4 thrombocytopenia in 4.1% and 1.6%, respectively; and grade 3/4 neutropenia in 1.8% and 0.8%, respectively. Conclusions: Ra-223 significantly improved OS and delayed time to first SRE, including first use of EBRT for pain, in CRPC patients with bone metastases. The safety profiles were similar between treatment groups and remained highly favorable for Ra-223, despite the sizeable proportion of patients in both groups who received prior or concomitant EBRT. Ra-223 is an effective therapy with a very favorable safety profile and may provide a new standard of care for treating CRPC patients with bone metastases. Author Disclosure: H.M. Sandler: E. Research Grant; ASTRO-ACR research funding for RTOG trials. G. Consultant; Bayer/Algeta – advisory board, Astellas/Medivation – advisory board, Varian – consultant. S. Nilsson: F. Honoraria; Algeta ASA – advisory board. G. Consultant; Algeta ASA – advisory board. C. Parker: F. Honoraria; Bayer. G. Consultant; Algeta ASA (uncompensated). J. Garcia-Vargas: A. Employee; Bayer HealthCare Pharmaceuticals. K. Staudacher: A. Employee; Algeta ASA. L. Stock Options; Algeta ASA. P. Hoskin: None.